The global benign prostatic hyperplasia treatment market grew at a CAGR of 8% during 2014-2019. Looking forward, IMARC Group expects the global market to continue its moderate growth during 2020-2025. Benign prostatic hyperplasia (BPH) refers to non-cancerous growth of the prostate gland that causes urethra blockage. This disorder generally results in the retention of urine, formation of bladder stones, incontinence due to overfilling, increased sensitivity of the bladder, and urinary tract infections. Some commonly used treatment methods for BPH include prescription drugs, mono drug and combination therapy, Phyto-therapies, and minimally-invasive (MI) and invasive surgeries. Resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants are some of the standard instruments used in BPH treatment surgeries.
Request for a free sample copy of this report: https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market/requestsample
The rising prevalence of urological disorders across the globe, coupled with the growing geriatric population, is currently driving the market growth. Furthermore, the increasing consumer awareness towards the availability of efficient and minimally-invasive treatment procedures for BPH is also propelling the market. Moreover, various advancements in the medical sector have led to the development of transurethral resection of the prostate (TURP) as an efficient treatment technique. TURP is an endoscopic electrosurgical procedure that removes a portion of the prostate gland to reduce the obstruction caused by abnormal growth. In addition to this, the rising healthcare expenditures and improving healthcare infrastructures will continue to drive the market growth in the coming years.
Market Overview:
Breakup by Treatment:
- Drug Class
- Alpha-Blockers
- 5-Alpha-reductase Inhibitors (5-ARIs)
- Phosphodiesterase-5 Enzyme Inhibitors
- Others
- Minimally Invasive Surgeries
- Transurethral Resection of the Prostate (TURP)
- Transurethral Incision of the Prostate (TUIP)
- Transurethral Microwave Thermotherapy (TUMT)
- Robotic Surgeries
- Prostatic Urethral Lifts
- Others
- Laser Therapy
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Explore full report with table of contents: https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market
Competitive Analysis:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.
Browse Related Reports:
Cystic Fibrosis Therapeutics Market
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Email: [email protected]
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal
The global benign prostatic hyperplasia treatment market is anticipated grow at a CAGR of 5.7% over the forecast period 2020-2020.
In this benign prostatic hyperplasia treatment market study, the following years are considered to predict the market footprint:History Year: 2014 - 2019Estimated Year: 2027Forecast Year: 2020 – 2027The business intelligence study of the benign prostatic hyperplasia treatment market covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume.
In a bid to recognize the growth prospects in the benign prostatic hyperplasia treatment market, the market study has been geographically fragmented into important regions that are progressing faster than the overall market.Fact.MR report suggests that patents of key Benign Prostatic Hyperplasia (treatments like Avodart, Jalyn, Cialis and Rapaflo will expire by the year 2027.
Though this will be a big turn down for the market players, it is eyed as an opportunity for different local and regional players.
Absence of major branded drugs opens window for these generic drugs to gain stronger foot hold in the market and generate greater revenue.
Major stake holders are highly concerned about this situation as they are making huge investments to developed advanced branded drugs.
The global benign prostatic hyperplasia treatment market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth.
With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each benign prostatic hyperplasia treatment market player in a comprehensive way.
Further, the benign prostatic hyperplasia treatment market report emphasizes the adoption pattern of the benign prostatic hyperplasia treatment market across various industries.The benign prostatic hyperplasia treatment market report highlights the following players:OlympusLISA LaserUrologix, LLCEndo International PlcTeleflex IncorporatedTeva Pharmaceutical Industries Ltd.The benign prostatic hyperplasia treatment market report examines the operating pattern of each player – new product launches, partnerships, and acquisitions – has been examined in detail.Important regions covered in the benign prostatic hyperplasia treatment market report include:North America (U.S., Canada)Europe (U.K., France)Asia Pacific (China, India)Latin America (Brazil, Mexico)The benign prostatic hyperplasia treatment market report takes into consideration the following segments by treatment:Drug ClassMinimally Invasive SurgeriesLaser TherapyRequest for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S_id=4412The benign prostatic hyperplasia treatment market report contain the following end use:HospitalsAmbulatory Surgical CentersSpecialty ClinicsThe benign prostatic hyperplasia treatment market report offers a plethora of insights which include:Changing consumption pattern among individuals globally.Historical and future progress of the global benign prostatic hyperplasia treatment market.Region-wise and country-wise segmentation of the benign prostatic hyperplasia treatment market to understand the revenue, and growth lookout in these areas.Accurate Year-on-Year growth of the global benign prostatic hyperplasia treatment market.Important trends, including proprietary technologies, ecological conservation, and globalization affecting the global benign prostatic hyperplasia treatment market.The benign prostatic hyperplasia treatment market report answers important questions which include:Which regulatory authorities have granted approval to the application of benign prostatic hyperplasia treatment market in healthcare industry?How will the global benign prostatic hyperplasia treatment market grow over the forecast period?Which end use industry is set to become the leading consumer of benign prostatic hyperplasia treatment market by 2027?What manufacturing techniques are involved in the production of the benign prostatic hyperplasia treatment market?Which regions are the benign prostatic hyperplasia treatment market players targeting to channelize their production portfolio?The benign prostatic hyperplasia treatment market report considers the following years to predict the market growth:Estimated Year: 2027Forecast Year: 2020 – 2027Why Choose Fact.MR?
Fact.MR follows a multi- disciplinary approach to extract information about various industries.
Our analysts perform thorough primary and secondary research to gather data associated with the market.
With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients.
Due to rising prostate issues including growth of major issues like prostate cancer, the market will likely reach US 12 billion in valuation by 2027.
The new cases of prostate ailments and minimally surgical procedures as well as potency and efficacy of the new drugs will drive growth of the benign prostatic hyperplasia treatment market.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=72273The rise of the disease among middle-aged men is a newly discovered and growing cause of concern in the healthcare sector.
The surrounding campaigns like national prostate health month, and rising awareness of the disease in the region are expected to create new opportunities for players in the benign prostatic hyperplasia treatment market.Request COVID Analysis on Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=72273Rising Cases Presents a Major Challenge for the Healthcare SectorCurrently, BPH presents the most common form of benign among various tumor cases.
It is estimated that there are over 8 million American men who are suffering from the condition and 22 million patients suffer its mild symptoms.
Moreover, the growth of the tumor can make it difficult to operate on other serious ailments like prostate cancer among people above 90, whose risks is as high as 60%.Request Customization on Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=72273Rising Elderly Population to Drive Robust Growth GloballyRising geriatric population globally is expected to create significant opportunities for expansion for existing players in the market.
The population is also expected to rise at the fastest rate in the US, Japan, UK, China, Brazil, among others.
According to recent Fact.MR study, the Benign Prostatic Hyperplasia Treatment market will grow during 2020-2027 period.
The Fact.MR study largely attributes the projected growth to technological advancements in manufacturing techniques, and rising demand for products in the sector.An Expert Perspective According to Fact.MR experts, the growth of Benign Prostatic Hyperplasia Treatment factors will remain key drivers to growth of the Benign Prostatic Hyperplasia Treatment market.
Additionally, the experts also believe Benign Prostatic Hyperplasia Treatment factors remain key concerns for end-consumers.
Request to View Sample of Report @ https://www.factmr.com/connectus/sample?flag=S_id=4412A Real Insight Fact.MR promises to ready new investors in the world of digital age with information from key stakeholders in the industry, objective forecasts, and independent analysis of a wide range of viewpoints.
The company leverages information from key stakeholders of information including World Bank, the UNO, WHO, among others to tackle challenges of investing with due diligence, and reliability.
An Apt Forecast For the Benign Prostatic Hyperplasia Treatment market, Fact.MR has considered 2015 as the base year for projections, while 2020-2025 period as the forecast period.
